Could Upstart Stock Double in 5 Years?

Upstart reported Q1 2026 revenue growth of 44% year over year, driven by a 77% increase in loan volumes, with adjusted EBITDA of $40.5 million and a 13% margin. Management guided to a 21% full-year EBITDA margin, while sell-side analysts expect revenue to grow 30.8% annually from 2025 to 2028. The article remains cautious on valuation and cyclicality, noting the stock trades 92% below its 2021 peak and that a 100% gain by 2031 is possible but unlikely.

Analysis

UPST is a leveraged macro call disguised as a software platform, which is why the market keeps assigning it a discount despite visible operating leverage. The key second-order effect is that when credit performs, the model looks like a secular AI winner; when delinquencies widen, it quickly reverts to a cyclical lender with opaque risk transfer economics. That asymmetry makes the stock behave more like a high-beta credit spread than a pure fintech multiple re-rating story.

The main bullish setup is not just revenue growth, but the possibility that improving automation and scale finally convert into durable free cash generation before the next credit turn. If management can sustain double-digit EBITDA margin expansion for several quarters, the market may stop anchoring to the prior drawdown and start pricing UPST against growth fintech peers rather than distressed lending comps. But the consensus is likely underestimating how fragile that setup remains to unemployment drift, rate volatility, and any tightening in funding partner appetite, which would hit volumes before the P&L visibly rolls over.

The contrarian view is that the market is already giving some credit for the rebound, so the next leg higher likely requires cleaner evidence of survivability through a softer macro patch, not just one strong quarter. In other words, the easy money is probably in the business model proving it can stay profitable across multiple credit seasons; absent that, valuation upside can compress quickly back into skepticism. For traders, the stock can work on momentum and revisions over the next 1-3 quarters, but it is still a poor candidate for a long-duration compounder thesis without macro insurance.

Key Decisions for Investors

• Tactically long UPST for 1-2 quarters into earnings revisions, but size as a trade not an investment; target a 20-30% move if loan growth and margin guidance both hold, with a hard stop if originations decelerate or credit commentary softens.
• Buy call spreads on UPST rather than outright stock to express upside while capping macro downside; favor 3-6 month tenor to capture sentiment improvement without paying for a full-cycle underwriting reset.
• Pair trade: long UPST / short a basket of higher-quality consumer credit or fintech names on any pullback if the market over-penalizes the stock; this isolates beta-to-credit-recovery while reducing broad sector risk.
• Avoid long-dated equity exposure until there is evidence of resilience through a weaker macro window; the probability of a 2x outcome looks too low relative to drawdown risk if unemployment or delinquencies turn.
• If owning UPST already, sell covered calls into strength; the stock can rerate sharply on good quarters, but the path dependency is high and upside is likely to be choppy rather than linear.